Herpes simplex glycoprotein vaccine - GlaxoSmithKline

Drug Profile

Herpes simplex glycoprotein vaccine - GlaxoSmithKline

Alternative Names: Genital herpes prophylaxis vaccine - GlaxoSmithKline; GSK208141; HSV gD-t2; Simplirix

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Developer GlaxoSmithKline; National Institute of Allergy and Infectious Diseases
  • Class Protein-vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 30 Sep 2010 Discontinued - Phase-III for Herpes simplex virus infections in Canada (IM)
  • 30 Sep 2010 Discontinued - Phase-III for Herpes simplex virus infections in European Union (IM)
  • 30 Sep 2010 Discontinued - Phase-III for Herpes simplex virus infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top